Company Overview and News

 
Huu-ay-aht First Nations and Western Forest Products Inc. Continue to Work Together Pursuant to the Reconciliation Protocol Agreement

2018-08-22 globenewswire
PORT ALBERNI, British Columbia, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Huu-ay-aht First Nations (“Huu-ay-aht”) and Western Forest Products Inc. (TSX: WEF) (“Western”) announce that they are working together to explore potential alternative ownership structures in Huu-ay-aht’s traditional territories pursuant to the Reconciliation Protocol Agreement. This collaborative effort may also involve other First Nations with traditional territories in the Alberni Valley over the next several years.
WFSTF WEF

 
Western Forest Products Inc. Announces New $250 Million Credit Facility

2018-08-08 globenewswire
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (“Western” or the “Company”) (TSX: WEF) announced today that it has entered into a new $250 million syndicated Credit Facility (the “Credit Facility”). The Credit Facility matures on August 1, 2022 and includes an accordion feature of $100 million.
WFSTF WEF

 
Western Forest Products Inc. Announces Renewal of Normal Course Issuer Bid

2018-08-03 globenewswire
VANCOUVER, British Columbia, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) announced today that it has received approval from the Toronto Stock Exchange ("TSX") to renew a normal course issuer bid ("NCIB") to purchase for cancellation up to 19,662,439 of its common shares, representing approximately 5% of the 393,248,787 common shares issued and outstanding as of August 3, 2018.
WFSTF WEF

 
Western Forest Products Inc. Confirms Record Date of Third Quarter 2018 Dividend

2018-08-03 globenewswire
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) is pleased to confirm that a quarterly dividend of $0.0225 per share will be paid with respect to the Company’s third fiscal quarter of 2018 to shareholders of record as at the close of business on Friday, August 31, 2018 and payable on Friday, September 14, 2018.
WFSTF WEF

2
CANADA STOCKS - TSX rises 0.19 percent

2018-07-25 reuters
SAN FRANCISCO, July 25 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 30.63 points, or 0.19 percent, to 16,420.76. * Leading the index were Toromont Industries Ltd, up 14.7 percent, FirstService Corp, up 6.8 percent, and Pretium Resources Inc , higher by 5.5 percent. * Lagging shares were Western Forest Products Inc, down 4.0 percent, Interfor Corp, down 3.5 percent, and CES Energy Solutions Corp, lower by 3.
WFSTF NGD TMTNF IFSPF ACBFF MEG NGDAF PVG NGD ACB PVG MEGEF FSV WEF

 
Western Forest Products Inc. Announces Release Date of Second Quarter 2018 Results and Conference Call Details

2018-06-29 globenewswire
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) second quarter 2018 financial and operating results will be released on Thursday, August 2, 2018.
WFSTF WEF

 
Western Forest Products Inc. Announces Election of Directors

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) announced today its voting results in respect of the election of all director nominees at its Annual and Special Meeting (the “Meeting”) held today as follows:
WFSTF WEF

 
Western Announces First Quarter 2018 Results

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) reported adjusted EBITDA of $43.0 million in the first quarter of 2018, compared to adjusted EBITDA of $34.0 million in the first quarter of 2017, and $38.9 million reported in the fourth quarter of 2017. Operating income prior to restructuring and other income was $32.6 million in the first quarter of 2018, compared to $23.
WFSTF WEF

 
Western Forest Products Inc. Increases Dividend

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) announced today that its Board of Directors has approved an increase of 12.5% in the quarterly dividend to $0.0225 per common share outstanding.
WFSTF WEF

 
Western Forest Products Inc. Announces Board of Director Changes

2018-04-11 globenewswire
VANCOUVER, British Columbia, April 11, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) announced today that Mr. Barrie Shineton will not be standing for re-election as a director at Western’s Annual and Special Meeting on May 3, 2018, and that Ms. Suzanne Blanchet has been proposed as a nominee for election to the Company’s Board of Directors (the “Board”).
WFSTF CADNF WEF

 
Western Forest Products Inc. Announces Release Date of First Quarter 2018 Results and Conference Call Details

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) first quarter 2018 financial and operating results will be released on Wednesday, May 2, 2018.
WFSTF WEF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 958211203